CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe July 4, 2024
GNS DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Genius Group Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Against Citadel Securities LLC and Virtu Americas LLC – GNS August 17, 2026
